基于医院信息系统电子医疗数据的复方苦参注射液治疗卵巢癌真实世界西药联合用药特征研究

发布时间：2018-10-16 14:38

【摘要】：目的:分析复方苦参注射液真实世界中联合用药规律,以期提高临床用药合理性,并为探索潜在治法及后续深入分析提供参考借鉴。方法:基于中国中医科学院中医临床基础医学研究所建立的大型医院信息系统电子医疗数据集成仓库,提取来自全国22家三甲医院诊断为恶性肿瘤且使用复方苦参注射液治疗患者的电子医疗数据,运用频数和百分比的描述性分析,以及基于Apriori算法的用药特征关联规则分析,对所记载的西药联合用药特征进行回顾研究。结果:共检索1510例使用复方苦参注射液且临床诊断为卵巢癌患者电子医疗数据。西药类别的保肝药、抗肿瘤化疗药、免疫调节药、5-HT受体阻断药、糖皮质激素药,与复方苦参注射液联用常见,且常用联合用药关联规则组合呈特定规律。结论:真实世界中复方苦参注射液治疗卵巢癌的临床联合用药特征显著,本研究为复方苦参注射液临床合理应用提供良好证据与借鉴。
[Abstract]:Objective: to analyze the law of combined use of compound Sophora flavescens injection in the real world in order to improve the rationality of clinical drug use and to provide reference for exploring potential therapy and further analysis. Methods: based on the large hospital information system electronic medical data integration warehouse established by Institute of Clinical basic Medicine of Chinese Academy of traditional Chinese Medicine, Electronic medical data were extracted from 22 third-class hospitals in China, which were diagnosed as malignant tumors and treated with compound Sophora flavescens injection. The frequency and percentage of the data were analyzed by descriptive analysis, and the association rules of drug use characteristics based on Apriori algorithm were analyzed. The characteristics of western medicine combined with medicine were reviewed and studied. Results: 1510 patients with ovarian cancer were treated with compound Sophora flavescens injection. Hepatoprotective drugs, anti-tumor chemotherapeutic drugs, immunomodulatory drugs, 5-HT receptor blockers, glucocorticoid drugs, and compound Sophora flavescens injection are commonly used together with compound Sophora flavescens injection. Conclusion: the clinical characteristics of compound Sophora flavescens injection in the treatment of ovarian cancer in the real world are remarkable. This study provides good evidence and reference for rational clinical application of compound Sophora flavescens injection.
【作者单位】：中国中医科学院中医临床基础医学研究所;中国人民大学统计学院;中国人民解放军海军总医院;
【基金】：国家重大新药创制科技重大专项(2015ZX09501004-001-002) 北京市中医药科技发展专项(JJ2014-53) 中国中医科学院自主选题项目(Z0427,PY1303)
【分类号】：R737.31

【相似文献】